Diabetic macular oedema therapeutic - SIMR Biotech
Alternative Names: SRXXXLatest Information Update: 28 Apr 2025
At a glance
- Originator SIMR Biotech
- Class Anti-inflammatories; Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Diabetic macular oedema
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for preclinical development in Diabetic-macular-oedema in China
- 18 Mar 2021 Diabetic macular oedema therapeutic - SIMR Biotech is available for licensing as of 18 Mar 2021. http://www.simrbio.com/en/business_development/
- 18 Mar 2021 Preclinical trials in Diabetic macular oedema in China (unspecified route) before March 2021 (SIMR Biotech pipeline, March 2021)